Purdue Withdraws Palladone At FDA's Request Due To Alcohol Interaction
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is immediately pulling extended-release hydromorphone off the market because of the potential for rapid release of the active ingredient into the bloodstream when the product is taken with alcohol, FDA and Purdue announce. FDA and Purdue note they have not received reports of alcohol-related serious adverse events with the opioid.
You may also be interested in...
King Signs On To Develop Pain Therapeutics’ Abuse-Resistant Oxycodone
The companies intend to file an NDA for the abuse-resistant oxycodone product Remoxy in 2007; King will fund Phase III.
King Signs On To Develop Pain Therapeutics’ Abuse-Resistant Oxycodone
The companies intend to file an NDA for the abuse-resistant oxycodone product Remoxy in 2007; King will fund Phase III.
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.